 Home > Active Ingredient News > Blood System > Leukemia: Donor-derived NK cells can reduce the recurrence rate of cancer patients after allogeneic hematopoietic stem cell transplantation

Leukemia: Donor-derived NK cells can reduce the recurrence rate of cancer patients after allogeneic hematopoietic stem cell transplantation

 Last Update: 2021-08-14
 Source: Internet
 Author: User

Tags

vitro cell culture

all natural moisturizer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Allogeneic hematopoietic stem cell transplantation (HSCT) is the preferred curative treatment strategy for patients with advanced hematological malignancies

Previous studies have shown that depending on the disease risk and transplant status, the recurrence rate of high-risk acute myeloid leukemia (AML) patients in remission can reach 50% or higher

Natural killer (NK) cells are a type of lymphocytes that can recognize and eliminate malignant cells and virus- infected cells

Transplantation results of the treatment group and the control group

The results showed that the patients’ median follow-up time was 24 months, the 2-year recurrence rates of the study group and the control group were 4% and 38%, and the disease-free survival rate (DFS) was 66% and 44%, respectively

The median follow-up time of the patients was 24 months, the 2-year recurrence rates of the study group and the control group were 4% and 38%, and the disease-free survival rate (DFS) was 66% and 44%, respectively

Immune reconstitution of treated patients

All in all, the results of the study revealed that it is safe to give donor-derived expanded NK cells after allogeneic hematopoietic stem cell transplantation, and is related to the early post-transplantation NK cell-led immune reconstitution, disease recurrence rate and the improvement of patients' DFS

After allogeneic hematopoietic stem cell transplantation, it is safe to give donor-derived expanded NK cells, and it is related to the early NK cell-led immune reconstitution, disease recurrence rate and the improvement of patients' DFS after transplantation

Decrease post-transplant relapse using donor-derived expanded NK-cells

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Gadusol Powder Gadusol76663-30-4

CAS No.: 76663-30-4

Industrial Grade

$1-1.01/G FOB

Food Additive Iron fumarate for Nutritional Iron Supplements

CAS No.: 141-01-5

Pharmacy Grade

$24-26/G FOB

Aminobenzoic Acid CAS 56-91-7

CAS No.: 56-91-7

Pharmaceutical Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.